Jacqueline A French1, Antonio Gil-Nagel2, Stefano Malerba2, Lynn Kramer2, Dinesh Kumar2, Emilia Bagiella2. 1. From the NYU Comprehensive Epilepsy Center (J.A.F.), New York; Hospital Ruber Internacional (A.G.-N.), Madrid, Spain; Mount Sinai Hospital (S.M., E.B.), New York; and the Eisai Neuroscience Product Creation Unit (L.K., D.K.), Woodcliff Lake, NJ. jacqueline.french@nyumc.org. 2. From the NYU Comprehensive Epilepsy Center (J.A.F.), New York; Hospital Ruber Internacional (A.G.-N.), Madrid, Spain; Mount Sinai Hospital (S.M., E.B.), New York; and the Eisai Neuroscience Product Creation Unit (L.K., D.K.), Woodcliff Lake, NJ.
Abstract
OBJECTIVE: To determine whether a novel endpoint of time to prerandomization monthly seizure count could be used to differentiate efficacious and nonefficacious therapies in clinical trials of new add-on antiepileptic drugs (AEDs). METHODS: This analysis used data from 3 randomized, double-blind, placebo-controlled phase III trials of perampanel as an add-on therapy in patients with epilepsy who were experiencing refractory partial seizures: studies 304 (ClinicalTrials.gov identifier NCT00699972), 305 (NCT00699582), and 306 (NCT00700310). Time to prerandomization monthly seizure count was evaluated post hoc for each trial, and findings were compared with the original primary outcomes (median percent change in seizure frequency and 50% responder rate). Outcomes were assessed for all partial-onset seizures, secondarily generalized (SG) tonic-clonic seizures only, and complex partial plus SG (CP + SG) seizures. RESULTS:Perampanel 4-12 mg significantly prolonged median time to prerandomization monthly seizure count, generally by more than 1 week, compared with placebo, across all 3 studies, consistent with the original primary outcomes. Analysis of SG seizures only, and CP + SG seizures, also indicated a significantly prolonged median time to prerandomization monthly seizure count with perampanel 8 mg and 12 mg compared with placebo. CONCLUSIONS:Time to prerandomization monthly seizure count is a promising novel alternative to the standard endpoints of median percent change in seizure frequency and 50% responder rates used in trials of add-on AEDs. Use of this endpoint could reduce exposure to placebo or ineffective treatments, thereby facilitating trial recruitment and improving safety.
RCT Entities:
OBJECTIVE: To determine whether a novel endpoint of time to prerandomization monthly seizure count could be used to differentiate efficacious and nonefficacious therapies in clinical trials of new add-on antiepileptic drugs (AEDs). METHODS: This analysis used data from 3 randomized, double-blind, placebo-controlled phase III trials of perampanel as an add-on therapy in patients with epilepsy who were experiencing refractory partial seizures: studies 304 (ClinicalTrials.gov identifier NCT00699972), 305 (NCT00699582), and 306 (NCT00700310). Time to prerandomization monthly seizure count was evaluated post hoc for each trial, and findings were compared with the original primary outcomes (median percent change in seizure frequency and 50% responder rate). Outcomes were assessed for all partial-onset seizures, secondarily generalized (SG) tonic-clonic seizures only, and complex partial plus SG (CP + SG) seizures. RESULTS:Perampanel 4-12 mg significantly prolonged median time to prerandomization monthly seizure count, generally by more than 1 week, compared with placebo, across all 3 studies, consistent with the original primary outcomes. Analysis of SG seizures only, and CP + SG seizures, also indicated a significantly prolonged median time to prerandomization monthly seizure count with perampanel 8 mg and 12 mg compared with placebo. CONCLUSIONS: Time to prerandomization monthly seizure count is a promising novel alternative to the standard endpoints of median percent change in seizure frequency and 50% responder rates used in trials of add-on AEDs. Use of this endpoint could reduce exposure to placebo or ineffective treatments, thereby facilitating trial recruitment and improving safety.
Authors: J Chris Sackellares; R Eugene Ramsay; B Joseph Wilder; Thomas R Browne; M Kent Shellenberger Journal: Epilepsia Date: 2004-06 Impact factor: 5.864
Authors: Daniel M Goldenholz; Joseph Tharayil; Robert Moss; Evan Myers; William H Theodore Journal: Ann Clin Transl Neurol Date: 2017-05-24 Impact factor: 4.511
Authors: Joseph Sullivan; Nicola Specchio; Orrin Devinsky; Stéphane Auvin; M Scott Perry; Adam Strzelczyk; Antonio Gil-Nagel; David Dai; Bradley S Galer; Arnold R Gammaitoni Journal: Epilepsia Date: 2021-10-22 Impact factor: 6.740
Authors: Sandra R P Kriechbaumer; Konrad Jurina; Franziska Wielaender; Henning C Schenk; Tanja A Steinberg; Sven Reese; Gesine Buhmann; Stefanie Doerfelt; Heidrun Potschka; Andrea Fischer Journal: Front Vet Sci Date: 2022-07-06